Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China

Cancer Epidemiology

Volumn 36, Issue 1, 2012, Pages 73-77

  Zhang, JinPing ^a   Yang, ShaoBin ^a   Xie, YuanYuan ^a   Chen, XiangYu ^a   Zhao, Ye ^a   He, DeZhi ^a   Li, JianSheng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Colorectal cancer; Feces; Methylation; Screening; Tissue factor pathway inhibitor 2

Indexed keywords

DNA; PLACENTA PROTEIN 5; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CHINA; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DNA DETERMINATION; FEASIBILITY STUDY; FECES ANALYSIS; FEMALE; FLUORESCENCE ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

CHINA; COLORECTAL NEOPLASMS; DNA METHYLATION; DNA, NEOPLASM; EARLY DETECTION OF CANCER; FECES; FEMALE; GLYCOPROTEINS; HUMANS; MALE; MIDDLE AGED; OCCULT BLOOD; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84855826568     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.04.006     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006. CA Cancer J Clin 2006, 56(2):106-130.
2. Fengju S., Guanglin W., Kexin C. Incidence of colon cancer in Tianjin China, 1981-2000. Asia Pac J Public Health 2005, 17(1):22-25.
3. Frazier A.L., Colditz G.A., Fuchs C.S., Kuntz K.M. Cost-effectiveness of screening for colorectal cancer in the general population. JAMA 2000, 284(15):1954-1961.
4. Winawer S., Fletcher R., Rex D., Bond J., Burt R., Ferrucci J., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale - update based on new evidence. Gastroenterology 2003, 124(2):544-560.
5. Ahlquist D.A., Skoletsky J.E., Boynton K.A., Harrington J.J., Mahoney D.W., Pierceall W.E., et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000, 119(5):1219-1227.
6. Dong S.M., Traverso G., Johnson C., Geng L., Favis R., Boynton K., et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001, 93(11):858-865.
7. Traverso G., Shuber A., Levin B., Johnson C., Olsson L., Schoetz D.J., et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002, 346(5):311-320.
8. Traverso G., Shuber A., Olsson L., Levin B., Johnson C., Hamilton S.R., et al. Detection of proximal colorectal cancers through analysis of faecal DNA. Lancet 2002, 359(9304):403-404.
9. Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., Turnbull B.A., Ross M.E. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004, 351(26):2704-2714. Colorectal Cancer Study Group.
10. Ahlquist D.A., Klatt K.K., Harrington J.J., Cunningham J.M. Novel use of hypermethylated DNA markers in stool for detection of colorectal cancer: a feasibility study. Gastroenterology 2002, 122:A40.
11. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L., et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005, 97(15):1124-1132.
12. Petko Z., Ghiassi M., Shuber A., Gorham J., Smalley W., Washington M.K., et al. Aberrantly methylated CDKN2A MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005, 11(3):1203-1209.
13. Lenhard K., Bommer G.T., Asutay S., Schauer R., Brabletz T., Göke B., et al. Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. Clin Gastroenterol Hepatol 2005, 3(2):142-149.
14. Leung W.K., To K.F., Man E.P., Chan M.W., Bai A.H., Hui A.J., et al. Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clin Chem 2004, 50(11):2179-2182.
15. Belshaw N.J., Elliott G.O., Williams E.A., Bradburn D.M., Mills S.J., Mathers J.C., et al. Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(9):1495-1501.
16. Muller H.M., Oberwalder M., Fiegl H., Morandell M., Goebel G., Zitt M., et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening?. Lancet 2004, 363(9417):1283-1285.
17. Zou H., Osborn N.K., Harrington J.J., Klatt K.K., Molina J.R., Burgart L.J., et al. Frequent methylation of eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2005, 14(4):830-834.
18. Glöckner S.C., Dhir M., Yi J.M., McGarvey K.E., Van Neste L., Louwagie J., et al. Methylation of TFPI2 in Stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009, 69(11):4691-4699.
19. Boynton K.A., Summerhayes I.C., Ahlquist D.A., Shuber A.P. DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 2003, 49(7):1058-1065.
20. Kariya Y., Kato K., Hayashizaki Y., Himeno S., Tarui S., Matsubara K. Revision of consensus sequence of human Alu repeats - a review. Gene 1987, 53(1):1-10.
21. Schneider T., Osl F., Friess T., Stockinger H., Scheuer W.V. Quantification of human Alu sequences by real-time PCR-an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis 2002, 19(7):571-582.
22. Zijlstra A., Mellor R., Panzarella G., Aimes R.T., Hooper J.D., Marchenko N.D., et al. A quantitative analysis of rate limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res 2002, 62(23):7083-7092.
23. Brussel A., Sonigo P. Analysis of early human immunodeficiency virus type 1 DNA synthesis by use of a new sensitive assay for quantifying integrated provirus. J Virol 2003, 77(18):10119-10124.
24. Grady W.M., Markowitz S.D. Genetic epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002, 3:101-128.
25. Mandel J.S., Church T.R., Bond J.H., Ederer F., Geisser M.S., Mongin S.J., et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000, 343(22):1603-1607.
26. Mandel J.S., Bond J.H., Church T.R., Snover D.C., Bradley G.M., Schuman L.M., et al. Reducing mortality from colorectal cancer by screening for fecal occult blood: Minnesota colonoscopy cancer control study. N Engl J Med 1993, 328(19):1365-1371.
27. Kronborg O., Fenger C., Olsen J., Jørgensen O.D., Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996, 348(9040):1467-1471.
28. Hardcastle J.D., Chamberlain J.O., Robinson M.H., Moss S.M., Amar S.S., Balfour T.W., et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996, 348(9040):1472-1477.
29. St John D.J., Young G.P., Alexeyeff M.A., Deacon M.C., Cuthbertson A.M., Macrae F.A., et al. Evaluation of new occult blood tests for detection of colorectal neoplasia. Gastroenterology 1993, 104(6):1661-1668.
30. Allison J.E., Tekawa I.S., Ransom L.J., Adrain A.L. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med 1996, 334(3):155-159.
31. Castiglione G., Zappa M., Grazzini G., Mazzotta A., Biagini M., Salvadori P., et al. Immunochemical vs. guaiac faecal occult blood tests in a population-based screening programme for colorectal cancer. Br J Cancer 1996, 74(1):141-144.
32. Morikawa T., Kato J., Yamaji Y., Wada R., Mitsushima T., Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005, 129(2):422-428.
33. Syngal S., Chung D., Willet C., Schoetz D., Schroy P., Stoffel E., et al. The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment. Gastroenterology 2003, 124(Suppl. 1):A5.
34. Tagore K.S., Lawson M.J., Yucaitis J.A., Gage R., Orr T., Shuber A.P., et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003, 3(1):47-53.
35. Wong C.M., Ng Y.L., Lee J.M., Wong C.C., Cheung O.F., Chan C.Y., et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007, 45(5):1129-1138.
36. Sato N., Parker A.R., Fukushima N., Miyagi Y., Iacobuzio-Donahue C.A., Eshleman J.R., et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005, 24(5):850-858.
37. Itzkowitz S., Brand R., Jandorf L., Durkee K., Millholland J., Rabeneck L., et al. A simplified, on invasive stool DNA test for colorectal cancer detection. Am. J. Gastroenterol. 2008, 103(11):2862-2870.